Adnan N, Haq M, Akter S, Sajal S, Islam M, Mou T
Vaccines (Basel). 2024; 12(5).
PMID: 38793733
PMC: 11125736.
DOI: 10.3390/vaccines12050482.
Marchese A, Rousculp M, Macbeth J, Beyhaghi H, Seet B, Toback S
J Infect Dis. 2023; 230(2):e496-e502.
PMID: 37992183
PMC: 11326839.
DOI: 10.1093/infdis/jiad519.
Gupta S, Goswami S, Anand A, Naman N, Kumari P, Sharma P
Immunol Res. 2023; 71(4):565-577.
PMID: 37041424
PMC: 10089693.
DOI: 10.1007/s12026-023-09373-5.
Sudjaritruk T, Mueangmo O, Saheng J, Winichakoon P, Salee P, Wongjak W
Vaccines (Basel). 2023; 11(3).
PMID: 36992147
PMC: 10051392.
DOI: 10.3390/vaccines11030564.
Shafaati M, Bagherzadeh K, Lotfinia M, Karimi H, Teimoori A, Razazian M
Heliyon. 2023; 9(3):e14108.
PMID: 36873499
PMC: 9968494.
DOI: 10.1016/j.heliyon.2023.e14108.
Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population.
Lounis M, Aouissi H, Abdelhadi S, Rais M, Belkessa S, Bencherit D
Vaccines (Basel). 2022; 10(11).
PMID: 36366290
PMC: 9698301.
DOI: 10.3390/vaccines10111781.
Perception and Acceptance of Using Different Generic Types of COVID-19 Vaccine, the "Mix-and-Match" Strategy, in Saudi Arabia: Cross-Sectional Web-Based Survey.
Alqurashi A, Sindy E, Dosh H, Khayat S, Alqarna L, Sodagar W
Int J Environ Res Public Health. 2022; 19(21).
PMID: 36360769
PMC: 9657038.
DOI: 10.3390/ijerph192113889.
Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.
Liu S, Kang M, Zhao N, Zhuang Y, Li S, Song T
Med Rev (2021). 2022; 2(2):169-196.
PMID: 35862507
PMC: 9274757.
DOI: 10.1515/mr-2021-0021.
Revival of the heterologous prime-boost technique in COVID-19: An outlook from the history of outbreaks.
Siddiqui A, Adnan A, Abbas M, Taseen S, Ochani S, Essar M
Health Sci Rep. 2022; 5(2):e531.
PMID: 35229055
PMC: 8866911.
DOI: 10.1002/hsr2.531.
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.
Kantarcioglu B, Iqbal O, Lewis J, Carter C, Singh M, Lievano F
Clin Appl Thromb Hemost. 2022; 28:10760296211056648.
PMID: 35167393
PMC: 8851053.
DOI: 10.1177/10760296211056648.
Global implication of booster doses of COVID-19 vaccine.
Kunal S, Ray I, Ish P
Infez Med. 2022; 29(4):643-647.
PMID: 35146376
PMC: 8805474.
DOI: 10.53854/liim-2904-20.
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.
Nguyen T, Quach T, Tran T, Phuoc H, Nguyen H, Vo T
Biomed Pharmacother. 2022; 147:112650.
PMID: 35066301
PMC: 8767802.
DOI: 10.1016/j.biopha.2022.112650.
T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants.
Nguyen T, Cohen C, Rowntree L, Bull M, Hachim A, Kedzierska K
Front Med (Lausanne). 2022; 8:793102.
PMID: 35004764
PMC: 8739267.
DOI: 10.3389/fmed.2021.793102.
Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities.
Ghattas M, Dwivedi G, Lavertu M, Alameh M
Vaccines (Basel). 2021; 9(12).
PMID: 34960236
PMC: 8708925.
DOI: 10.3390/vaccines9121490.
COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.
Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N
J Med Virol. 2021; 94(4):1294-1299.
PMID: 34796525
PMC: 8661746.
DOI: 10.1002/jmv.27463.
A Mix and Match Approach to COVID-19 Vaccinations: Does Nigeria Have a Choice?.
Al-Mustapha A, Oyewo M, Olugbon A, Elelu N
Front Public Health. 2021; 9:755974.
PMID: 34790644
PMC: 8591124.
DOI: 10.3389/fpubh.2021.755974.
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.
Chatterjee B, Thakur S
Expert Rev Vaccines. 2021; 21(1):47-67.
PMID: 34697980
PMC: 8787839.
DOI: 10.1080/14760584.2022.1997601.
